83RO Trastuzumab pamirtecan (T-Pam/DB-1303/BNT323) in patients (pts) with previously treated, HER2-expressing, advanced endometrial cancer (EC): Overall survival (OS) and efficacy in pt subgroups of a phase II dose-expansion cohort
T-Pam, a HER2-targeted ADC, has demonstrated antitumor activity in pts with pretreated, advanced, HER2-expressing recurrent EC. Encouraging response rates were observed across all HER2 expression levels (IHC 1+, 2+ or 3+) with the highest response in IHC3+ (confirmed ORR: ∼73% per local testing). Here, we report data from key subgroups and OS from this cohort.
Authors
- J. Liu
- L. Wang
- O. Yeku
- Lou Hk
- H. Zheng
- N. Lang
- W. Growdon
- D.L. Richardson
- V. Makker
- H. Mu
- F. Musa
- M. Wenger
- K.N. Moore
- M. Ni
- Z. Guo
- M. Carney
- B. Pothuri
- H. Yu
- X. Wu
- J. Lee
Institutions
- Memorial Sloan Kettering Cancer Center (US)
- Hawaii Pacific University (US)
- Sun Yat-sen University (CN)
- Peking University (CN)
- Susan Thompson Buffett Foundation (US)
- Zhengzhou University (CN)
- NYU Langone Health (US)
- Massachusetts General Hospital (US)
- Fudan University Shanghai Cancer Center (CN)
- Swedish Medical Center (US)
- Cancer Center of Hawaii (US)
- Peking University Cancer Hospital (CN)
- Zhejiang Cancer Hospital (CN)
- Shandong Tumor Hospital (CN)
- Oklahoma State University Oklahoma City (US)
- BioNTech (Germany) (DE)
- Henan Cancer Hospital (CN)
- Sun Yat-sen University Cancer Center (CN)
- Center for Cancer Research (US)
- BioNTech (United States) (US)
- Cell Biologics (United States) (US)
- Shandong First Medical University (CN)
- University of Chinese Academy of Sciences (CN)
Publication Details
- Journal
- ESMO Open
- Published
- 2026-07-01
- DOI
- https://doi.org/10.1016/j.esmoop.2026.108100
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00